SERUM LEVELS LEUKEMIA INHIBITORY FACTOR PLAYS A CRUCIAL ROLE IN THE PROGRESSION TO ESSENTIAL HYPERTENSION



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of the present study was to evaluate the prognostic value of LIF levels in patients with еssential hypertension (EH). Methods: serum LIF, IGF-1 and IGFBP1 levels were measured with an enzyme-linked immunosorbent assay in 200 patients with II stage ЕН during 3 year period. Results: The mean serum LIF concentration in patients with ЕН was significantly higher than that in control subjects (7,54 pg/ml л - 95% confidence interval [7,34-7,74] pg/ml vs 1,25 pg/ml - 95% confidence interval [1,20-1,31] pg/ml, p<0,001). Thus, level LIF and associated IGF-1/IGFBP1 play a critical role in the progression to arterial hypertension (adverse vascular remodeling and cardiac hypertrophy), but the association showed a different pattern for men and women. Logistic regression analysis showed that LIF concentrations were the independent predictors of future events. The three year survival free of stroke and myocardial infarction were significantly lower in patients with LIF concentrations in the III-IV quartiles (7,55-15,5 pg/ml) and IGF-1concentrations in the lowest quartile (values <113 ng/ml) than in those with values <7,5 pg/ml and more 113 pg/ml. Conclusions. We reported a significant association between high serum LIF levels and risk of cardiovascular events (myocardial infarction, stroke) in patients with ЕН. LIF serum concentration may serve as prognosis criteria for progression to ЕН.

Full Text

Restricted Access

About the authors

O A Radaeva

Mordovian State N. P. Ogariov University

Email: radaevamed@mail.ru

A S Simbirtsev

State Research Institute of Highly Pure Biopreparations

References

  1. Idris-Khodja N., Mian M.O., Paradis P., Schiffrin E.L. Dual opposing roles of adaptive immunity in hypertension // Eur. Heart J. - 2014. - Vol. 14, № 35 (19). - P. 1238-1244.
  2. Mathieu M.-E., Saucourt C., Mournetas V. et al. LIF-Dependent Signaling: New Pieces in the Lego // Stem Cell Rev. - 2012. - Vol. 8 (1). - P. 1-15.
  3. Wu R., Wyatt E., Chawla K. et al. Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production // Mol. Med. - 2012. - Vol. 4. - H. 633-646.
  4. Zgheib C., Zouein F. A., Kurdi M., Booz G.W. Differential STAT3 Signaling in the Heart: Impact of Concurrent Signals and Oxidative Stress // JAK-STAT. - 2012. - Vol. 1 (2). - P. 101-110.
  5. Gonzalez A., Ravassa S., Loperena I. et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure // J. Hypertens. - 2007. - Vol. 25 (10). - P. 2148-2157.
  6. Funamoto M., Fujio Y., Kunisada K. et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes // J. Biol. Chem. - 2000. - Vol. 275 (14). - P. 10561-10566.
  7. Zouein F.A., Kurdi M., Booz G.W. Dancing rhinos in stilettos: The amazing saga of the genomic and nongenomic actions of STAT3 in the heart // JAKSTAT. - 2013 - Vol. 2 (3). - Р. 101-110.
  8. Port M.D., Gibson R.M., Nathanson N.M. Differential stimulation-induced receptor localization in lipid rafts for interleukin-6 family cytokines signaling through the gp130/leukemia inhibitory factor receptor complex // J. Neurochem. - 2007. - Vol. 101(3). - P. 782-793.
  9. Thusen J.H., Borensztajn K.S., Moimas S. et al. IGF-1 Has Plaque-Stabilizing Effects in Atherosclerosis by Altering Vascular Smooth Muscle Cell Phenotype // The American Journal of Pathology. - 2011. - Vol. 178 (2). - P. 924-934.
  10. Herbert A., Cruickshank J.K., Laurent S., Boutouyrie P. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. // Eur. Heart J. - 2014. - Vol. 35 (44). - P. 3122-3133.
  11. Fujio Y., Maeda M., Mohri T. et al. Glycoprotein 130 cytokine signal as a therapeutic target against cardiovascular diseases // J. Pharmacol. Sci. - 2011. - Vol. 117 (4). - P. 213-222.
  12. Радаева О.А., Симбирцев А.С. Гендерные особенности системы интерлейкина-1 у женщин с эссенциальной артериальной гипертензией // Цитокины и воспаление. - 2014. - Т. 3, № 13. - С. 31-38.
  13. Turner N.A., Das A., Warburton P. et al. Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts // Am. J. Physiol. - 2009. - Vol. 297 (3). - Р. 1117-1127.
  14. Dey D., Shepherd A., Pachuau J., Migue M. Leukemia inhibitory factor regulates trafficking of T-type Ca2+ channels // Am. J. Physiol. Cell Physiol. - 2011. - Vol. 300 (3). - Р. 576-587.
  15. Wang M., Tsai B.M., Reiger K.M. et al. 17-beta-Estradiol decreases p38 MAPK-mediated myocardial inflammation and dysfunction following acute ischemia // J. Mol. Cell Cardiol. - 2006. - Vol. 40 (2). - P. 205-212.
  16. Rajwani A., Ezzat V., Smith J. et al. IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against // Atherosclerosis Diabetes. - 2012. - Vol. 61 (4). - P. 915-924.
  17. Unden A.-L., Elofsson S., Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study // Clinical Endocrinology. - 2005. - Vol. 63. - P. 94-102.
  18. Hu D., Pawlikowska L., Kanaya A. et al. Serum Insulin-Like Growth Factor-1 Binding Proteins 1 and 2 and Mortality in Older Adults: The Health, Aging, and Body Composition Study // J. of the American Geriatrics Society. - 2009. - Vol. 57. - P. 1213-1218.
  19. Young A.R., Ali C., Duretete A., Vivien D. Neuroprotection and stroke: time for a compromise. Journal of Neurochemistry. - 2009. - Vol. 103. - P. 1302-1309.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Radaeva O.A., Simbirtsev A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies